Investor Presentaiton
Core Operating Profit
Decreased by 9.3 Bn JPY (Decreased by 9.1 Bn JPY excl. forex impact)
FY2021 Q1 Results
43.7
Revenue
Cost of Sales
SG&A Expenses
R&D Expenses
Forex Impact
FY2022 Q1 Results
34.4
17.4
16.2
14.4
Positive Factors
14.2
7.9
Negative Factors
Revenue
+16.2
incl. forex impact of +17.3
Cost of Sales
-14.2
Daiichi-Sankyo
(Bn JPY)
Improvement in cost of sales ratio by change in product mix
SG&A Expenses
+7.9
Increase in expenses related to Enhertu due to an increase in profit share of
gross profit with AstraZeneca
R&D Expenses
+14.4
Increase in 3ADCS* R&D investments
Forex Impact
+17.4 (Profit Decreased)
Cost of Sales
+3.7
SG&A Expenses
+7.2
R&D Expenses
+6.5
* 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062)
and 3) Patritumab deruxtecan (HER3-DXd, U3-1402)
6View entire presentation